Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022

Rachel A. Freedman(Dana-Farber Cancer Institute), Nancy U. Lin(Dana-Farber Cancer Institute), Julie R. Nangia(Unknown), Sandro Santagata(Harvard University), Elizabeth C. Randall(Brigham and Women's Hospital), Carey K. Anders(Duke University), Beverly Moy(Global Cancer Institute), Antonio C. Wolff(Johns Hopkins University), Juan M. Marte(Dana-Farber Cancer Institute), Ian E. Krop(Yale Cancer Center), Catherine Van Poznak(University of Michigan), Nathalie Y.R. Agar(Texas Endosurgery Institute), Nadine Tung(Beth Israel Deaconess Medical Center), Kelly M. Silvestri(Dana-Farber Cancer Institute), Robyn Burns(Breast Cancer Research Foundation), Timothy J. Moynihan(Mayo Clinic), Rebecca Gelman(Dana-Farber Cancer Institute), Begoña Giménez(Brigham and Women's Hospital), Eric P. Winer(University of Vermont), Kathryn P. Componeschi(Dana-Farber Cancer Institute), Mothaffar F. Rimawi(Baylor College of Medicine), Nuhad K. Ibrahim(The University of Texas MD Anderson Cancer Center), Christine M. Cotter(Dana-Farber Cancer Institute), Ian F. Dunn(University of Oklahoma), Shannon L. Puhalla(NSABP Foundation), Michelle Melisko(University of California, San Francisco), Kimberly Blackwell(Duke University), Roisín M. Connolly(Johns Hopkins University)
Clinical Breast Cancer
August 22, 2019
Cited by 28


Related Papers